Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Skin Tight: Dermatology Specialty Leo Pharma To Buy Peplin for $287.5 Million

This article was originally published in The Pink Sheet Daily

Executive Summary

The dermatology market is increasingly attractive for deal makers, as Leo's all-cash acquisition of Peplin demonstrates.

You may also be interested in...



Leo Pharma Aims To Extend Reach Of Dermatology Business With Global Expansion And Picato’s Green Light For Europe

Danish dermatology specialist Leo Pharma is hunting for new pipeline assets after its next major product – Picato gel – got the green light from Europe’s top regulator.

LEO Plays Up Rapid Action Of Picato For Actinic Keratosis

Newly approved plant-based gel works in just a few days of treatment, rather than the weeks required for some competitors.

LEO Pharma Pays $1 Billion To Get Its Psoriasis Drugs Back From Warner Chilcott

American dermatology dream: Danish specialty pharma plans to establish beachhead up in New Jersey after buying back U.S. rights.

Related Content

Topics

UsernamePublicRestriction

Register

PS070055

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel